The US Food and Drug Administration has suspended the licence of a vaccine developed by Valneva SE to prevent chikungunya virus infection following 32 serious adverse event reports, including 21 hospitalisations and three deaths. The vaccine, Ixchiq (chikungunya vaccine, life), was given an accelerated approval by the FDA in November 2023 and since then has been approved in several other countries, some of which are also reviewing patient data. Valneva is expected to start a post-marketing study of the vaccine on 1 October to further assess the risks.
